Literature DB >> 20713024

(1)H MR spectroscopy in Friedreich's ataxia and ataxia with oculomotor apraxia type 2.

Isabelle Iltis1, Diane Hutter, Khalaf O Bushara, H Brent Clark, Myron Gross, Lynn E Eberly, Christopher M Gomez, Gülin Oz.   

Abstract

BACKGROUND AND AIM: Friedreich's ataxia (FRDA) and ataxia with oculomotor apraxia type 2 (AOA2) are the two most frequent forms of autosomal recessive cerebellar ataxias. However, brain metabolism in these disorders is poorly characterized and biomarkers of the disease progression are lacking. We aimed at assessing the neurochemical profile of the pons, the cerebellar hemisphere and the vermis in patients with FRDA and AOA2 to identify potential biomarkers of these diseases.
METHODS: Short-echo, single-voxel proton ((1)H) magnetic resonance spectroscopy data were acquired from 8 volunteers with FRDA, 9 volunteers with AOA2, and 38 control volunteers at 4T. Disease severity was assessed by the Friedreich's Ataxia Rating Scale (FARS).
RESULTS: Neuronal loss/dysfunction was indicated in the cerebellar vermis and hemispheres in both diseases by lower total N-acetylaspartate levels than controls. The putative gliosis marker myo-inositol was higher than controls in the vermis and pons in AOA2 and in the vermis in FRDA. Total creatine, another potential gliosis marker, was higher in the cerebellar hemispheres in FRDA relative to controls. Higher glutamine in FRDA and lower glutamate in AOA2 than controls were observed in the vermis, indicating different mechanisms possibly leading to altered glutamatergic neurotransmission. In AOA2, total N-acetylaspartate levels in the cerebellum strongly correlated with the FARS score (p<0.01).
CONCLUSION: Distinct neurochemical patterns were observed in the two patient populations, warranting further studies with larger patient populations to determine if the alterations in metabolite levels observed here may be utilized to monitor disease progression and treatment. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713024      PMCID: PMC2949538          DOI: 10.1016/j.brainres.2010.08.030

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  57 in total

Review 1.  N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction.

Authors:  J B Clark
Journal:  Dev Neurosci       Date:  1998       Impact factor: 2.984

2.  Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS.

Authors:  P J Pouwels; J Frahm
Journal:  Magn Reson Med       Date:  1998-01       Impact factor: 4.668

3.  MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter.

Authors:  H Vrenken; F Barkhof; B M J Uitdehaag; J A Castelijns; C H Polman; P J W Pouwels
Journal:  Magn Reson Med       Date:  2005-02       Impact factor: 4.668

4.  Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study.

Authors:  Myron Gross; Michael Steffes; David R Jacobs; Xinhua Yu; Linda Lewis; Cora E Lewis; Catherine M Loria
Journal:  Clin Chem       Date:  2004-10-28       Impact factor: 8.327

5.  Multinuclear NMR studies on the energy metabolism of glial and neuronal cells.

Authors:  A Brand; C Richter-Landsberg; D Leibfritz
Journal:  Dev Neurosci       Date:  1993       Impact factor: 2.984

Review 6.  Magnetic resonance imaging in degenerative ataxic disorders.

Authors:  I E Ormerod; A E Harding; D H Miller; G Johnson; D MacManus; E P du Boulay; B E Kendall; I F Moseley; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

7.  Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy.

Authors:  P J Pouwels; B Kruse; G C Korenke; X Mao; F A Hanefeld; J Frahm
Journal:  Neuropediatrics       Date:  1998-10       Impact factor: 1.947

8.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra.

Authors:  S W Provencher
Journal:  Magn Reson Med       Date:  1993-12       Impact factor: 4.668

9.  Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress.

Authors:  J D Morrow; L J Roberts
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

10.  Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion.

Authors:  V Campuzano; L Montermini; M D Moltò; L Pianese; M Cossée; F Cavalcanti; E Monros; F Rodius; F Duclos; A Monticelli; F Zara; J Cañizares; H Koutnikova; S I Bidichandani; C Gellera; A Brice; P Trouillas; G De Michele; A Filla; R De Frutos; F Palau; P I Patel; S Di Donato; J L Mandel; S Cocozza; M Koenig; M Pandolfo
Journal:  Science       Date:  1996-03-08       Impact factor: 47.728

View more
  12 in total

1.  Cerebellar neurochemical alterations in spinocerebellar ataxia type 14 appear to include glutathione deficiency.

Authors:  Sarah Doss; Jan Leo Rinnenthal; Tanja Schmitz-Hübsch; Alexander U Brandt; Sebastian Papazoglou; Silke Lux; Stephan Maul; Jens Würfel; Matthias Endres; Thomas Klockgether; Martina Minnerop; Friedemann Paul
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

2.  Consensus paper: radiological biomarkers of cerebellar diseases.

Authors:  Leonardo Baldarçara; Stuart Currie; M Hadjivassiliou; Nigel Hoggard; Allison Jack; Andrea P Jackowski; Mario Mascalchi; Cecilia Parazzini; Kathrin Reetz; Andrea Righini; Jörg B Schulz; Alessandra Vella; Sara Jane Webb; Christophe Habas
Journal:  Cerebellum       Date:  2015-04       Impact factor: 3.847

3.  Axial diffusivity is increased in the degenerating superior cerebellar peduncles of Friedreich's ataxia.

Authors:  Riccardo Della Nave; Andrea Ginestroni; Stefano Diciotti; Elena Salvatore; Andrea Soricelli; Mario Mascalchi
Journal:  Neuroradiology       Date:  2010-12-03       Impact factor: 2.804

Review 4.  Quantitative in vivo neurochemical profiling in humans: where are we now?

Authors:  Jessica McKay; Ivan Tkáč
Journal:  Int J Epidemiol       Date:  2016-10-29       Impact factor: 7.196

5.  Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis.

Authors:  Ian Cheong; Małgorzata Marjańska; Dinesh K Deelchand; Lynn E Eberly; David Walk; Gülin Öz
Journal:  Neurochem Res       Date:  2017-04-03       Impact factor: 3.996

Review 6.  Magnetic resonance imaging biomarkers in patients with progressive ataxia: current status and future direction.

Authors:  Stuart Currie; Marios Hadjivassiliou; Ian J Craven; Iain D Wilkinson; Paul D Griffiths; Nigel Hoggard
Journal:  Cerebellum       Date:  2013-04       Impact factor: 3.847

7.  Combined Cerebellar Proton MR Spectroscopy and DWI Study of Patients with Friedreich's Ataxia.

Authors:  Laura Ludovica Gramegna; Caterina Tonon; David Neil Manners; Antonella Pini; Rita Rinaldi; Stefano Zanigni; Claudio Bianchini; Stefania Evangelisti; Filippo Fortuna; Valerio Carelli; Claudia Testa; Raffaele Lodi
Journal:  Cerebellum       Date:  2017-02       Impact factor: 3.847

Review 8.  Demographic reporting across a decade of neuroimaging: a systematic review.

Authors:  Elijah Sterling; Hannah Pearl; Zexuan Liu; Jason W Allen; Candace C Fleischer
Journal:  Brain Imaging Behav       Date:  2022-09-17       Impact factor: 3.224

9.  Longitudinal 1H MRS of rat forebrain from infancy to adulthood reveals adolescence as a distinctive phase of neurometabolite development.

Authors:  Jonathan J Morgan; Gale A Kleven; Christina D Tulbert; John Olson; David A Horita; April E Ronca
Journal:  NMR Biomed       Date:  2013-01-16       Impact factor: 4.044

10.  The differential diagnosis of Huntington's disease-like syndromes: 'red flags' for the clinician.

Authors:  Davide Martino; Maria Stamelou; Kailash P Bhatia
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-09-19       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.